Search results for ''

About us

Read more »

Published on 02/01/2016

Home

Developing therapeutics for diseases with impaired kidney function

Published on 02/01/2016

ENYO Pharma strengthens its arsenal of hepatitis B potential therapies

Lyon, November 25, 2015 – ENYO Pharma, a biopharmaceutical company focused on developing treatments for acute and chronic viral infections, is announcing that it has obtained a license to a key patent enabling it to use agonists of the farnesoid X receptor (FXR) as hepatitis B treatments.

Read more »

Published on 25/11/2015

POXEL and ENYO Pharma Sign License Agreement on POXEL’s FXR Agonists Program

Lyon, France, May 6, 2015 – POXEL SA (Euronext: POXEL), a biopharmaceutical company developing innovative drugs to treat type 2 diabetes, and ENYO Pharma SAS, a newly-formed company focused on the treatment of acute and chronic viral infections, today announced the signing of a license agreement under which ENYO will gain access to Poxel’s FXR (farnesoid X receptor) agonist compounds for infection-related indications with Poxel retaining rights regarding therapeutic indications centered on its core expertise.

Read more »

Published on 06/05/2015

Libération – Ebola: l’OMS décrète une «urgence de santé publique de portée mondiale»

http://www.liberation.fr/planete/2014/08/07/l-epidemie-d-ebola-progresse-le-bilan-approche-les-mille-morts_1076939

Published on 07/08/2014